Summary
We are pleased to continue our series of web conferences: In a new format we interview personalities from the industry, academia and politics. Third guest: Dr. Deepak Nath.
Dr. Deepak Nath will share with us how his organization was impacted by the Covid-19 crisis and why this antibodies test is a major milestone in the fight against COVID-19. We will discuss with him the risk management structure of his company, its business continuity in those uncertain times, as well as possible implications for the post-Corona period.
On August 20, 2020 Bloomberg announced that Siemens Healthineers AG is the first big company to gain U.S. Food and Drug Administration clearance for a test that gauges the concentration of long-lasting antibodies flowing through a person’s blood.
Headquartered in Erlangen, Germany, Siemens Healthineers is a separately managed and publicly traded healthcare business of Siemens AG. As one of the largest medtech companies in the world, its core businesses include Diagnostics, Imaging, and Advanced Therapies.
Past Interviews:
- Dr. Achim von Leoprechting, CEO of TECAN Group on 13. May 2020
- Dr. Martin Janssen, CEO of Ecofin Group on 8. April 2020
Prof. Walter Farkas will carry out a 30-minute interview, and then give room for your questions in a 20-minute Q&A session. This event is in english.
Please register for this event, so we can plan accordingly.
Presenters
Dr. Deepak Nath: President of Laboratory Diagnostics at Siemens Healthineers
interviewed by Walter Farkas
Web Conference – before you join
In order to make the most of this conference we kindly ask you to:
- Make sure you have a reliable internet connection
- Find a quiet space (if possible) and use your headphones
- Be ready 5-10min before and test your microphone and your camera before you start
- Mute your microphone when not speaking
- Use the chat for questions, we will direct the questions to the moderator to be answered during Q&A
-
Interview Dr. Deepak Nath
15. September 2020
18:00 - 19:00